Search

Displaying results 6671 - 6680 of 10000 in total
  1. Drug

    TAS-102

    go.drugbank.com/drugs/DB08937
    Investigational

    TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer.

  2. Drug

    Repinotan

    go.drugbank.com/drugs/DB06506
    Investigational

    Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.

  3. Drug

    Lucatumumab

    go.drugbank.com/drugs/DB06360
    Investigational

  4. Drug

    Pegvisomant

    go.drugbank.com/drugs/DB00082
    ApprovedInvestigational

    Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediat...

  5. Drug

    Telatinib

    go.drugbank.com/drugs/DB15393
    Investigational

    Telatinib is under investigation in clinical trial NCT03817411 (Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer).

  6. Drug

    Chiauranib

    go.drugbank.com/drugs/DB16124
    Investigational

    Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).

  7. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

  8. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  9. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

  10. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.